Latest News

Vesalius Biocapital III Fund closes at €120 million

© fotolia.com/sdecoret


by TG

Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.

The fund includes commitments of €30m from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. Vesalius Biocapital III has already executed three investments. These include investments in Forendo, a clinical stage drug development company focusing on novel treatments in women’s health; Mecuris, a Munich-based medtech developing an easy-to-use online platform for customizable and 3D-printed orthotics and prosthetics; and SWORD Health, a tech-enabled provider of physical therapy, pairing its AI-powered digital therapists with human clinical teams to recover patients faster and better.

Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health with the goal of investing in 10 to 15 companies over the lifetime of the fund.

Drug from worms dampens autoimmune response

According to researchers headed by Julia Esser-von Bieren from Helmholtz Center Munich, Germany, the products from parasitic helminths might help...

COVID-19: Solnatide approved for compassionate use

The more COVID-19 patients reach advanced disease stages according to the eight-level WHO disease scale, the more important it becomes to treat...

First drug found to reduce COVID-19-mortality

According to Principal Investigator Peter Horby from the University of Oxford, the cheap immunomodulatory drug dexamethasone helped reducing...

British scientists start Phase II on COVID-19 vaccine

The study sponsored by AstraZeneca plc is the third pivotal test of a COVID-19 vaccine that expresses SARS-CoV-2 antigens directly in human cells or...

BioGeneration Ventures closes BGV IV Fund at €105m

Investors into the oversubscribed BVG IV gathered existing actors — such as Bristol Myers Squibb, the European Investment Fund, and Schroder Adveq —...

Bone Therapeutics bags €11m

Regenerative medicine specialist Bone Therapeutics said it will use the proceeds of €11m to advance two key assets of its allogeneic cell therapy...

Bacterial colonisation differs by tumour type

An international research team from Israel, the US, Italy, and the Netherlands profiled the microbiomes of more than 1,500 individual tumours across...